" class="no-js "lang="en-US"> Marinus Pharmaceuticals Appoints Christine Silverstein to Board
Thursday, March 23, 2023

Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee.

“Ms. Silverstein brings to our Board deep capital markets expertise and extensive corporate strategic planning, business development, compliance and risk management experience,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “Her financial and strategic acumen combined with her background in neurology and rare disease make her an outstanding addition to Marinus’ Board of Directors as we seek to grow the ZTALMY® (ganaxolone) franchise, advance our late-stage programs and expand our clinical pipeline.”

Ms. Silverstein is a seasoned finance executive with experience across both private and public biopharmaceutical companies and an aptitude for implementing strong financial strategy, corporate partnering, financial reporting, cash management and improving efficiencies within organizations. Ms. Silverstein currently serves as Chief Financial Officer (CFO) of Excision Biotherapeutics, Inc., and most recently served as CFO of Emendo Biotherapeutics (acquired in December 2020 by AnGes, Inc.). She previously operated in various senior executive roles within the biotechnology industry, including Abeona Therapeutics, as CFO and Principal Financial Officer, and SCO Capital Partners, a New York-based biotechnology venture fund, as managing director. Ms. Silverstein began her career in the financial services industry before moving to capital markets advisory firms, where she was instrumental in advising clients on transaction considerations and formulating effective U.S. public listing and financing strategies.

“Marinus is a dynamic company from its pipeline to its people, and I am thrilled to join at this pivotal juncture following the successful launch of its first product, ZTALMY,” said Christine Silverstein. “I look forward to working with the Marinus Board and management as the company continues advancing its clinical programs and commercial capabilities to fulfill its mission of improving the lives of people affected by rare epilepsies and seizure disorders.”

A member of CHIEF and Women in Bio, two esteemed networks of exceptional female leaders, Ms. Silverstein holds a Bachelor of Science from the Peter Tobin College of Business at St. John’s University and has earned accreditations from the Financial Industry Regulatory Authority (FINRA) and Harvard University. She currently serves on the board of Abeona Therapeutics Inc., a biopharmaceutical company focused on rare pediatric diseases.

  1. OliX Pharmaceuticals Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia Read more
  2. Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer Read more
  3. BIOTECanada Welcomes Government of Canada’s Strategy on Improving Access to Care for Patients with Rare Diseases Read more
  4. Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read more
  5. Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application Read more